FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307886382> ?p ?o ?g. }

• W4307886382 endingPage "170" @default.
• W4307886382 startingPage "156" @default.
• W4307886382 abstract "<b><i>Introduction:</i></b> Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. <b><i>Methods:</i></b> Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (<i>n</i> = 68) were screened and classified according to their PD, 6 weeks after treatment initiation (early PD; <i>n</i> = 13). Of these, 4 patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (<i>n</i> = 60) and evaluated in patients treated with lenvatinib. <b><i>Results:</i></b> No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&#x3c;333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs. 227 days; HR: 2.41, 95% CI: 1.22–4.80, <i>p</i> = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. <b><i>Conclusion:</i></b> Baseline low serum CXCL9 (&#x3c;333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab." @default.
• W4307886382 created "2022-11-06" @default.
• W4307886382 creator A5003655394 @default.
• W4307886382 creator A5011042847 @default.
• W4307886382 creator A5014225991 @default.
• W4307886382 creator A5020231124 @default.
• W4307886382 creator A5022230206 @default.
• W4307886382 creator A5023584248 @default.
• W4307886382 creator A5024316557 @default.
• W4307886382 creator A5024713150 @default.
• W4307886382 creator A5025757104 @default.
• W4307886382 creator A5029167813 @default.
• W4307886382 creator A5031216911 @default.
• W4307886382 creator A5040976202 @default.
• W4307886382 creator A5046391549 @default.
• W4307886382 creator A5047266289 @default.
• W4307886382 creator A5047927868 @default.
• W4307886382 creator A5048212539 @default.
• W4307886382 creator A5050339468 @default.
• W4307886382 creator A5051179719 @default.
• W4307886382 creator A5051255682 @default.
• W4307886382 creator A5053029290 @default.
• W4307886382 creator A5053862181 @default.
• W4307886382 creator A5054771915 @default.
• W4307886382 creator A5057000189 @default.
• W4307886382 creator A5059132728 @default.
• W4307886382 creator A5065209679 @default.
• W4307886382 creator A5070335872 @default.
• W4307886382 creator A5075045544 @default.
• W4307886382 creator A5081579462 @default.
• W4307886382 creator A5091222313 @default.
• W4307886382 date "2022-10-31" @default.
• W4307886382 modified "2023-09-30" @default.
• W4307886382 title "Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment" @default.
• W4307886382 cites W1524533358 @default.
• W4307886382 cites W1971837077 @default.
• W4307886382 cites W1978454134 @default.
• W4307886382 cites W2070088507 @default.
• W4307886382 cites W2079586464 @default.
• W4307886382 cites W2560499218 @default.
• W4307886382 cites W2618332520 @default.
• W4307886382 cites W2787358630 @default.
• W4307886382 cites W2888056309 @default.
• W4307886382 cites W2899174828 @default.
• W4307886382 cites W2903271964 @default.
• W4307886382 cites W2908573150 @default.
• W4307886382 cites W2942473792 @default.
• W4307886382 cites W2947849947 @default.
• W4307886382 cites W2949278321 @default.
• W4307886382 cites W2952311394 @default.
• W4307886382 cites W2954583220 @default.
• W4307886382 cites W2982017357 @default.
• W4307886382 cites W2988194539 @default.
• W4307886382 cites W2999924529 @default.
• W4307886382 cites W3012582547 @default.
• W4307886382 cites W3015552590 @default.
• W4307886382 cites W3021228866 @default.
• W4307886382 cites W3025022288 @default.
• W4307886382 cites W3027991621 @default.
• W4307886382 cites W3036542274 @default.
• W4307886382 cites W3041069444 @default.
• W4307886382 cites W3080167134 @default.
• W4307886382 cites W3088005314 @default.
• W4307886382 cites W3100629716 @default.
• W4307886382 cites W3104225545 @default.
• W4307886382 cites W3110927983 @default.
• W4307886382 cites W3119526003 @default.
• W4307886382 cites W3134771778 @default.
• W4307886382 cites W3162270595 @default.
• W4307886382 cites W3176511332 @default.
• W4307886382 cites W3179949770 @default.
• W4307886382 cites W3180003360 @default.
• W4307886382 cites W3183248180 @default.
• W4307886382 cites W3212903603 @default.
• W4307886382 cites W4200090702 @default.
• W4307886382 cites W4213062169 @default.
• W4307886382 cites W4243625103 @default.
• W4307886382 cites W4280549889 @default.
• W4307886382 cites W4283325186 @default.
• W4307886382 doi "https://doi.org/10.1159/000527759" @default.
• W4307886382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37325489" @default.
• W4307886382 hasPublicationYear "2022" @default.
• W4307886382 type Work @default.
• W4307886382 citedByCount "4" @default.
• W4307886382 countsByYear W43078863822023 @default.
• W4307886382 crossrefType "journal-article" @default.
• W4307886382 hasAuthorship W4307886382A5003655394 @default.
• W4307886382 hasAuthorship W4307886382A5011042847 @default.
• W4307886382 hasAuthorship W4307886382A5014225991 @default.
• W4307886382 hasAuthorship W4307886382A5020231124 @default.
• W4307886382 hasAuthorship W4307886382A5022230206 @default.
• W4307886382 hasAuthorship W4307886382A5023584248 @default.
• W4307886382 hasAuthorship W4307886382A5024316557 @default.
• W4307886382 hasAuthorship W4307886382A5024713150 @default.
• W4307886382 hasAuthorship W4307886382A5025757104 @default.
• W4307886382 hasAuthorship W4307886382A5029167813 @default.
• W4307886382 hasAuthorship W4307886382A5031216911 @default.
• W4307886382 hasAuthorship W4307886382A5040976202 @default.

• next